AI Summary
✦ ClarthaGland Pharma is a pharmaceutical manufacturer focused on injectable formulations across India and international markets. Its revenue centers on injectable products, complex APIs such as heparins and peptides, and therapies spanning anti-infectives, oncology, diabetes, and blood-related conditions. Q1 FY27’s reported 20% revenue growth and volume surge indicate stronger demand, supporting operating leverage and improving margins. Profit growth of 47.1% exceeded 14.7% revenue growth, while improving margins point to better earnings conversion. However, 10.5% ROE is constrained by leverage, with debt-to-equity at 2.74. At 42.3 times earnings, the shares appear rich versus growth, despite positive momentum and recent results. The key open question is whether volume-led growth can offset balance-sheet pressure and justify the premium valuation.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 14 analysts
Fundamentals
Fundamentals institutional score is 62 using EVA spread proxy -1.5%; growth durability 94.6.
Valuation
Valuation institutional score is 12 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 34 using mean target upside -4.1%; dispersion penalty 20.3; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 0 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is skewing constructive on impact and recency. Based on 12 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. market sentiment provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 65.0% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +4.58). Confidence: 87%.
Live forward EPS implies next-12-month EPS of ₹96.56. Applying the stock's normalized valuation corridor produces a fair range of ₹2,339.65 to ₹2,678.57, with base value near ₹2,482.56 (-14.1% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹96.56
Forward P/E
29.9x
Base Fair Value
₹2,482.56
Fair Range
₹2,339.65 - ₹2,678.57
Upside To Base
-14.1%
Estimate Source
Live forward EPS
Growth Estimate
+96.4%
5Y Average
29.38
Current
42.43
Overvalued
27.74
Undervalued
24.23
5Y Average
17.72
Current
25.59
Overvalued
19.55
Undervalued
14.42
5Y Average
5.13
Current
7.42
Overvalued
5.67
Undervalued
4.18
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.1x Undervalued | -24% vs avg | -6.3% |
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.2x Premium | +70% vs avg | +35.1% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 18.9x Undervalued | -59% vs avg | +14.5% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.9x Undervalued | -22% vs avg | +12.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.5x Undervalued | -16% vs avg | -14.9% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.0x Fair | -15% vs avg | +31.3% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +99% vs avg | +115.3% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 30.2x Undervalued | -34% vs avg | -3.9% |
GLAND PHARMA LIMITED trades in line with peers (42.3x vs avg 45.9x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include CIPLA LTD, TORRENT PHARMACEUTICALS L, LUPIN LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.26K CrMar 2026Latest net profit
₹420 CrMar 2026Latest EPS
₹25.52Mar 2026Net margin
40.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 785 | 884 | 1,011 | 1,098 | 1,175 | 1,012 | 1,063 | 1,011 | 1,030 | 1,039 | 1,074 | 1,178 | 1,262 |
| Expenses + | 616 | 625 | 664 | 728 | 742 | 718 | 699 | 620 | 636 | 680 | 699 | 756 | 754 |
| Operating Profit | 169 | 259 | 347 | 369 | 433 | 294 | 364 | 391 | 394 | 359 | 375 | 422 | 508 |
| OPM % | 22% | 29% | 34% | 34% | 37% | 29% | 34% | 39% | 38% | 35% | 35% | 36% | 40% |
| Other Income + | -18 | 35 | 41 | 43 | 47 | 48 | 58 | 65 | 44 | 55 | 83 | 36 | 106 |
| Interest | 2 | 2 | 1 | 1 | 5 | 1 | 0 | 18 | 3 | 7 | 4 | 0 | 6 |
| Depreciation | 38 | 39 | 40 | 40 | 43 | 41 | 42 | 44 | 43 | 44 | 45 | 45 | 43 |
| Profit before tax | 112 | 254 | 347 | 372 | 433 | 300 | 380 | 394 | 391 | 362 | 409 | 412 | 565 |
| Tax % | 29% | 26% | 26% | 26% | 26% | 26% | 26% | 25% | 26% | 26% | 26% | 25% | 26% |
| Net Profit + | 79 | 188 | 258 | 277 | 321 | 223 | 282 | 295 | 290 | 269 | 302 | 308 | 420 |
| EPS in Rs | 4.81 | 11.39 | 15.64 | 16.81 | 19.51 | 13.53 | 17.10 | 17.91 | 17.60 | 16.34 | 18.33 | 18.69 | 25.52 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release